[Skip to Content]
[Skip to Content Landing]
Editor's Correspondence
February 10, 2003

The Use of Niacin in Diabetes Mellitus

Arch Intern Med. 2003;163(3):369. doi:10.1001/archinte.163.3.369-a

I have 3 comments on the article by Grundy et al1 regarding the use of extended-release niacin for the treatment of dyslipidemia with type 2 diabetes mellitus. First, the references of the article include major errors that created significant confusion. In fact, 9 of the 26 listed references (reference numbers 7, 14, 17, 18, 19, 20, 22, 23, and 24) were either misplaced or irrelevant to the content of the corresponding text. For example, on page 1569, the authors reported the effects of the 0.9% reduction in hemoglobin A1c on diabetic vascular complications in the United Kingdom Prospective Diabetes Study (UKPDS), stating reference number 7 as the corresponding reference. However, reference number 7 on page 1576 was related to a study published in 1987 about the determinants of coronary artery disease in juvenile-onset diabetes. On the other hand, the UKPDS was published in 1998 and only involved patients with type 2 diabetes.2

First Page Preview View Large
First page PDF preview
First page PDF preview